Osteopontin as a Regulator of Colorectal Cancer Progression and Its Clinical Applications.
Katyana Amilca-SebaMichèle SabbahAnnette K LarsenJerome Alexandre DenisPublished in: Cancers (2021)
A high expression of the phosphoprotein osteopontin (OPN) has been associated with cancer progression in several tumor types, including breast cancer, hepatocarcinoma, ovarian cancer, and colorectal cancer (CRC). Interestingly, OPN is overexpressed in CRC and is associated with a poor prognosis linked to invasion and metastasis. Here, we review the regulation and functions of OPN with an emphasis on CRC. We examine how epigenetic and genetic regulators interact with the key signaling pathways involved in this disease. Then, we describe the role of OPN in cancer progression, including proliferation, survival, migration, invasion, and angiogenesis. Furthermore, we outline the interest of using OPN as a clinical biomarker, and discuss if and how osteopontin can be implemented as a routine assay in clinical laboratories for monitoring CRC patients. Finally, we discuss the use of OPN an attractive, but challenging, therapeutic target.
Keyphrases
- poor prognosis
- long non coding rna
- papillary thyroid
- signaling pathway
- end stage renal disease
- squamous cell
- newly diagnosed
- cell migration
- ejection fraction
- chronic kidney disease
- transcription factor
- gene expression
- endothelial cells
- peritoneal dialysis
- childhood cancer
- high throughput
- prognostic factors
- epithelial mesenchymal transition
- pi k akt
- young adults
- squamous cell carcinoma
- patient reported outcomes
- vascular endothelial growth factor
- binding protein